Key result
Direct oral anticoagulants are safer than vitamin K antagonists in patients with compensated liver cirrhosis and atrial fibrillation, but remain contraindicated in Child-Pugh class C liver cirrhosis.
Why the study?
Anticoagulation in patients with liver cirrhosis remains debated due to impaired coagulation balance and exclusion from pivotal trials, prompting an evaluation of recent data in decompensated liver cirrhosis.
Do direct oral anticoagulants prevent thromboembolic complications safely compared to vitamin K antagonists in patients with atrial fibrillation and liver cirrhosis?
Systematic Review
Do direct oral anticoagulants prevent thromboembolic complications safely compared to vitamin K antagonists in patients with atrial fibrillation and liver cirrhosis?
DOACs (specifically apixaban and dabigatran) are preferred over VKAs for stroke prevention in AF patients with Child-Pugh B cirrhosis, but remain contraindicated in Child-Pugh C.
Answers are grounded in this paper and cite their sources.
Supports DOAC preference over VKAs in compensated cirrhosis with AF; extends observational data but leaves randomized confirmation open.
Atrial fibrillation is frequently diagnosed in patients with liver cirrhosis, especially in those with non-alcoholic steatohepatitis or alcoholic etiology. Anticoagulant treatment is recommended for thromboembolic protection in patients with atrial fibrillation. Considering the impaired coagulation balance in liver cirrhosis, predisposing patients to bleed or thrombotic events, the anticoagulant treatment is still a matter of debate. Although patients with liver cirrhosis were excluded from the pivotal studies that confirmed the efficacy and safety of the anticoagulant treatment in patients with atrial fibrillation, data from real-life cohorts demonstrated that the anticoagulant treatment in patients with liver cirrhosis could be safe. This review aimed to evaluate the recent data regarding the safety and efficacy of anticoagulant treatment in patients with decompensated liver cirrhosis. Direct oral anticoagulants are safer than warfarin in patients with compensated liver cirrhosis. In Child-Pugh class C liver cirrhosis, direct oral anticoagulants are contraindicated. New bleeding and ischemic risk scores should be developed especially for patients with liver cirrhosis, and biomarkers for bleeding complications should be implemented in clinical practice to personalize this treatment in a very difficult population represented by decompensated liver cirrhosis patients.
No takes yet. Share an insight, caveat, or question.
Gîrleanu et al. (2023) conducted a systematic review in Atrial fibrillation and liver cirrhosis. Direct oral anticoagulants vs. Vitamin K antagonists was evaluated on Thromboembolic complications and bleeding. Direct oral anticoagulants are safer than vitamin K antagonists in patients with compensated liver cirrhosis and atrial fibrillation, but remain contraindicated in Child-Pugh class C liver cirrhosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: